Ocular Therapeutix, Inc. will present at the J.P. Morgan Healthcare Conference on January 13, 2025, in San Francisco.Quiver AI SummaryOcular Therapeutix, Inc. announced that it will present at the 43rd...
Ocular Therapeutix announced significant progress in the SOL-1 trial for AXPAXLIâ„¢, aimed at treating wet AMD.Quiver AI SummaryOcular Therapeutix, Inc. has announced that it has successfully randomized...
Jeffrey S. Heier, the Chief Scientific Officer of $OCUL ($OCUL), sold 2,948 shares of the company on 11-25-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately...
Ocular Therapeutix will participate in December conferences highlighting advancements in retinal disease therapies and ongoing clinical trials.Quiver AI SummaryOcular Therapeutix, Inc., a biopharmaceutical...
Ocular Therapeutix: Q3 Earnings Snapshot